US Anticoagulation Therapy Market 2017-2025: Industry Share, Size, Emerging Trends, Regional Outlook, Growth Drivers & Restraints, Demand Analysis.
Thrombotic diseases caused by cancer progression have been reported as one of the major causes of cancer associated morbidity and mortality along with cancer invasiveness and infectious complications in US. Moreover, anticoagulant therapy with heparin and heparin-like drugs, or vitamin K antagonists, or the Direct Oral Anticoagulants, is seeing an extended application in cancer patients and offers prolonged life expectancy to oncology patients for whom blood activation and thrombotic events have a variable incidence, depending on cancer type. The Anticoagulation Therapy market is expected to reach USD 12.56 billion by 2025, growing at a CAGR of 7.87% during the forecast period. Novel oral anticoagulant (NOACs) is the top performing segment as an alternative to anticoagulant. Increasing number of patients with lifelong medical aid therapy, growing prevalence of blood vessel thromboembolism, arrhythmia, and stroke, acceptance of NOAC’s is raising revenue in the market, rising outpatient anticoagulation therapy, increasing number of pipeline products under clinical trials and rising heparin trade spurring the growth of anticoagulation therapy market. However, high cost of developing drugs and risk of malfunctions like increased bleeding is main issue with newer agents are expected to impact the target market negatively.
The NOACs segment led the anticoagulation therapy market for drugs in 2017 owing to emergence of many pharma companies to develop more secure and structured NOAC’s in future years. The in-office testing devices dominated the market for PT/INR testing devices in 2017, while home testing devices is the fastest growing segment at a CAGR of 7.88% among the PT/INR testing devices. On the basis of services, the testing services held the largest market share of the anticoagulation therapy market for clinics in 2017, on the account of cost effectiveness and instant result generation saving time.
The report covers the present ground scenario and the future growth prospects of the facility management market for 2017-2025 along with the market players’ analysis. We calculated the market size and revenue share on the basis of revenue generated from major players worldwide. Anticoagulation Therapy market is forecasted on the basis of revenue analysis, product benchmarking and strategic developments of key market players.
United States Anticoagulation Therapy Market Outlook 2017-2025, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the Anticoagulation Therapy market space. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. “United States Anticoagulation Therapy Market Report” also recognizes value chain analysis to understand the cost differentiation, pricing models to provide competitive advantage to the existing and new entry players.
Our United States Anticoagulation Therapy Market Report comprises of the following companies as the key players: C. H. Boehringer Sohn, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Daiichi Sankyo, Portola Pharmaceuticals, Roche, Abbott, Siemens, Alere and CoaguSense.